Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream. - Test2 - elhamkhani - TriplyDB

Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.

Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.

http://www.wikidata.org/entity/Q35632513

about

The toll-like receptor agonist imiquimod is active against prions Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratoses Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach.A phase II dose-ranging study of topical resiquimod to treat actinic keratosis.TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway Roles of the immune system in skin cancer.Immunomodulation by imiquimod in patients with high-risk primary melanoma Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection.The immunologic aspects of poxvirus oncolytic therapy Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.Current and emerging treatment strategies for the treatment of actinic keratosis.Molecular diagnostic strategies: a role in the practice of dermatology.Lmax and imiquimod 3.75%: the new standard in AK management.Therapeutic targeting of Toll-like receptors in cutaneous disorders.Patient satisfaction and reported outcomes on the management of actinic keratosis.A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin.Therapeutic effect of imiquimod on dextran sulfate sodium-induced ulcerative colitis in mice.Microarray analysis of aberrant gene expression in actinic keratosis: effect of the Toll-like receptor-7 agonist imiquimod.Association between the clinical and histopathological classifications of actinic keratosis and the efficacy of topical imiquimod treatment.Comparative study for the effect of photodynamic therapy, imiquimod immunotherapy and combination of both therapies on 40 lesions of actinic keratosis in Japanese patients.

P2860

Q28535404-55B17482-72D7-4152-9825-AABA628191A0 Q33302568-4B643F4D-58BD-43E8-AD2C-1BC18CF8851E Q34074154-A29FCFE8-ACBF-4E46-A8BD-E6E81E20B943 Q34299210-13AA146F-EEDF-4804-AC1F-D5AB63075CB6 Q34778360-9AE8C6A2-0A1D-46B0-9924-DBC5F2331229 Q35220395-62E3D6F7-0106-4EBE-82F3-5F625A98442F Q35403714-57480B7A-D4DF-442E-9328-491189FD7B80 Q35590166-CC598248-5E65-48C3-B7DE-C45F43229429 Q35724734-A02A9A7C-1D0B-463D-A955-B1B7A922B7A9 Q36115128-616EDEB3-22C3-4A3B-8721-8D2B4D0D259F Q37831354-606D9FF9-FE91-4956-A363-81EA7B7218C7 Q37857684-901E06A0-3970-4B29-92EE-10F7B87BE491 Q38052162-C3220E46-E2B6-4AEB-BAB1-E2B86056A841 Q38282402-20138125-EE0B-46D6-A355-4851FC424DF9 Q38550117-E8AE9389-B7CC-40F3-A310-D60C7A45B86E Q39335529-2D65DEC0-7AFF-4040-864D-911A5A0EB042 Q42403489-ADB7C771-6F9C-470F-87E8-59917D8CAC85 Q46165646-21CD3F5B-70FF-428A-B683-13F3C3F61B3A Q46943368-14457945-CEFF-4FAD-9B2D-4507AA8A9A23 Q48371523-D1B3BCC8-E6F1-4292-A6C2-5D4D76C4A138 Q54714574-C0A64F26-36F3-47F7-BD29-EA8734615B64

P2860

Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.

http://www.wikidata.org/entity/Q35632513

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Immune-mediated changes in act ...... tment with imiquimod 5% cream.

@ast

Immune-mediated changes in act ...... tment with imiquimod 5% cream.

@en

type

label

Immune-mediated changes in act ...... tment with imiquimod 5% cream.

@ast

Immune-mediated changes in act ...... tment with imiquimod 5% cream.

@en

prefLabel

Immune-mediated changes in act ...... tment with imiquimod 5% cream.

@ast

Immune-mediated changes in act ...... tment with imiquimod 5% cream.

@en

P1433

Q35632513-38D45BC7-9339-4ADD-BB0B-2383CDEF181A

P1476

Q35632513-553A76EB-46F4-4DE2-8FB2-B4CB36B11B30

P2093

Q35632513-04C6BD28-249E-49E4-84A5-F1D096970B36

Q35632513-2E954C4F-8A87-49E9-B522-9EB5FFB60B95

Q35632513-3B061C94-18D1-45A1-B751-B228B39AE03D

Q35632513-4647BDE6-A958-47CF-8E54-842B4568AD23

Q35632513-5F1BAC42-3BE8-46F3-8E45-92191736B825

Q35632513-6E26CFD5-D001-4FED-9654-5642A8176D75

Q35632513-9810E484-D5FA-41C2-B4D5-C3E670FE77BC

Q35632513-9B353D6A-4AAF-424D-9284-2DF14F42CC1E

Q35632513-A6B95B85-A1EE-49DA-91AB-20B7B0B3B9A5

Q35632513-E2966D1F-1730-436F-B0C6-5DEE2A8204A7

P2860

Q35632513-033491A5-AA34-4E56-B6D6-B40FB3D598FA

Q35632513-0390E1CE-A85B-4362-92EB-A9150B3B35A4

Q35632513-03ACC496-B4E1-468A-A3EA-611BFDCFABC6

Q35632513-096E6B9B-0FED-4EDC-87F2-06A7591C7894

Q35632513-09DCE67C-3345-4CA3-93DC-72C1187B3395

Q35632513-0A93110E-49EE-4525-A0CE-B50537EA51BA

Q35632513-0CDA390E-2247-4C9E-9D99-3DE2E3FBBD53

Q35632513-0D0FC34B-ABCF-4C8D-B505-EBADAFE2BF8D

Q35632513-114DA616-A615-490B-B965-9DB336F89D15

Q35632513-16344E93-5336-43F8-9C96-26EE520FAC68

P2888

Q35632513-1B14F862-3307-4543-A541-6B6AA80EECE9

P304

Q35632513-6838636A-EFCC-4E4F-9225-75C026C969C2

P31

Q35632513-CCA91AAA-9C63-40F2-99A0-013ADB7BC606

P356

Q35632513-42A5CAD6-2DD8-410F-B1A1-26576AF544EA

P478

Q35632513-3E872D4F-7B8F-4DC5-9D62-BA0C3410825A

P577

Q35632513-87FD93F2-9084-4211-A0B4-F2A7E981191F

P5875

Q35632513-90D3DEF0-C1D0-484A-820D-266FBBCDB026

P6179

Q35632513-1027DD16-C28C-417A-A710-0FFE1F221366

P698

Q35632513-09756157-EDDD-41C1-AE88-9816169B366B

P932

Q35632513-BC352766-CF1B-4256-A648-FEECBB9D2343

P356

P1433

Journal of Translational Medicine

P1476

Immune-mediated changes in act ...... tment with imiquimod 5% cream.

@en

P2093

Abel Torres

http://www.w3.org/2001/XMLSchema#string

Barbara J Bulbulian

http://www.w3.org/2001/XMLSchema#string

Herbert B Slade

http://www.w3.org/2001/XMLSchema#string

James Lee

http://www.w3.org/2001/XMLSchema#string

Jizhong Jin

http://www.w3.org/2001/XMLSchema#string

Leslie Storey

http://www.w3.org/2001/XMLSchema#string

Makala Anders

http://www.w3.org/2001/XMLSchema#string

Richard L Miller

http://www.w3.org/2001/XMLSchema#string

Shalini Raghavan

http://www.w3.org/2001/XMLSchema#string

Woubalem Birmachu

http://www.w3.org/2001/XMLSchema#string

P2860

APCs express DCIR, a novel C-type lectin surface receptor containing an immunoreceptor tyrosine-based inhibitory motif

Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells

IFNs activate toll-like receptor gene expression in viral infections

Viperin (cig5), an IFN-inducible antiviral protein directly induced by human cytomegalovirus

Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells

Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector

IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction

mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties

Differential gene expression by integrin beta 7+ and beta 7- memory T helper cells

Polarized monocyte response to cytokine stimulation

P2888

P304

7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-5-7

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6547677

http://www.w3.org/2001/XMLSchema#string

P6179

1018931494

http://www.w3.org/2001/XMLSchema#string

P698

17257431

http://www.w3.org/2001/XMLSchema#string

P932

1796543

http://www.w3.org/2001/XMLSchema#string